HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Futura Strikes Deal To Commercialize Erectile Dysfunction Gel In Middle East

Executive Summary

UK R&D firm Futura Medical strikes third commercial agreement for its drug-free erectile dysfunction treatment MED3000, this time with Switzerland’s Labatec Pharma, which will take the drug-free gel to the Middle East. 

You may also be interested in...



People On The Move: Appointments At Futura Medical, Bayer And Maxwellia

The latest appointments in Europe's consumer health industry: Former Perrigo exec Jeff Needham joins Futura Medical; Bayer promotes Gomez to lead Swiss Consumer business; and Maxwellia appoints Al-Attbi to newly-created role.

Consumer Health Industry Ideally Placed To Lead And Benefit From Climate Fight

Consumer healthcare firms are perfectly placed to lead the charge in fighting climate change while benefitting from the transition to a greener, healthier world. However, taking advantage of the green opportunity means putting environmental, social and governance (ESG) at the center of how OTC companies measure and reward success and treating the health of people and planet as a single, related issue, argues Bayer Consumer Health's sustainability guru Daniella Foster. 

WHO Support A Game-Changer For Emerging Global Self-Care Movement, Resolution 'Likely'

Working alongside the consumer healthcare industry, the Self-Care Academic Research Unit (SCARU) is helping to build a global self-care movement that makes a World Health Organization resolution "very likely" in the next few years, says director Austen El-Osta.

Topics

UsernamePublicRestriction

Register

RS151791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel